Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin 2022-01-15 03:30
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency 2021-12-16 21:00
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split 2021-02-19 21:00
NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement 2020-09-09 21:00
China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government 2020-03-16 21:16
China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory 2020-01-16 21:00
China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency 2020-01-03 23:30
China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques 2019-09-11 19:00
China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019 2019-08-19 20:00
China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate 2019-08-12 20:00
China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production 2019-07-03 20:00
China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province 2019-05-22 23:20
China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing 2019-04-17 21:01
China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification 2019-04-02 18:30
China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018 2019-03-28 18:30
China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering 2019-01-04 20:30
China SXT Pharmaceuticals, Inc. Announces Effectiveness of Registration Statement on Form F-1 and Pricing the Initial Public Offering of its Ordinary Shares at $4.00 per Share 2018-09-29 05:15
1